Kintor PharmaceuticalKNTPF 20 Piotroski F-Score is 4 as of Jun. 29, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,339 Biotechnology companies, Kintor Pharmaceutical ranks better than 74.16% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kintor Pharmaceutical has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Kintor Pharmaceutical's Piotroski F-Score or its related term are showing as below:
KNTPF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 4
Current: 4
During the past 8 years, the highest Piotroski F-Score of Kintor Pharmaceutical was 4. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Kintor Pharmaceutical Piotroski F-Score Related Terms
Kintor Pharmaceutical Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNTPF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kintor Pharmaceutical's current Net Income (TTM) was -28.41.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kintor Pharmaceutical's current Cash Flow from Operations (TTM) was -24.10.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Kintor Pharmaceutical's return on assets of this year was -0.40155755. Kintor Pharmaceutical's return on assets of last year was -0.17520413.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Kintor Pharmaceutical's gearing of this year was 0.00235018. Kintor Pharmaceutical's gearing of last year was 0.02854174.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Kintor Pharmaceutical's current ratio of this year was 0.43303522. Kintor Pharmaceutical's current ratio of last year was 1.03031494.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Kintor Pharmaceutical's number of shares in issue this year was 449.773. Kintor Pharmaceutical's number of shares in issue last year was 430.724.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Kintor Pharmaceutical's gross margin of this year was 0.24590517. Kintor Pharmaceutical's gross margin of last year was -0.94614265.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Kintor Pharmaceutical's asset turnover of this year was 0.06558118. Kintor Pharmaceutical's asset turnover of last year was 0.00564327.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
1
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kintor Pharmaceutical has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Kintor Pharmaceutical (KNTPF) has a Piotroski F-Score of 4 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Kintor Pharmaceutical and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Kintor Pharmaceutical's Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, Kintor Pharmaceutical ranks #346 out of 1339 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Kintor Pharmaceutical's Piotroski F-Score too high?
Kintor Pharmaceutical's current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. Kintor Pharmaceutical's value of 4 is 33.3% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #346 out of 1339 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #346 out of 1339 companies for Piotroski F-Score. This puts Kintor Pharmaceutical in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Kintor Pharmaceutical's value of 4 is 33.3% above this benchmark. Historically, Kintor Pharmaceutical's own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Kintor Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 33.3% above the Biotechnology industry median of 3.00. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Piotroski F-Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score
Get the complete analysis for KNTPF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
